These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Five-grass pollen immunotherapy tablet: an update on the latest findings from clinical trials: an interview with Olivier de Beaumont. de Beaumont O, Wilkinson J. Immunotherapy; 2014; 6(10):1021-3. PubMed ID: 25428642 [Abstract] [Full Text] [Related]
25. Sam Ho on health system quality and population medicine. Interview by Nancy Houyoux. Ho S. J Healthc Qual; 2003; 25(6):25-7. PubMed ID: 14671853 [Abstract] [Full Text] [Related]
26. Treating MS without continuous immunosuppression: an interview with Luciano Rossetti. Rossetti L. Neurodegener Dis Manag; 2018 Apr; 8(2):69-71. PubMed ID: 29557715 [Abstract] [Full Text] [Related]
27. Interview: commercial translation of cell-based therapies and regenerative medicine: learning by experience. Interview by Emily Culme-Seymour. Haseltine WA. Regen Med; 2011 Jul; 6(4):431-5. PubMed ID: 21749201 [Abstract] [Full Text] [Related]
28. Ask The Experts: Pain management and end-of-life care. Fine PG. Pain Manag; 2012 Jul; 2(4):325-8. PubMed ID: 24654717 [Abstract] [Full Text] [Related]
29. Research and development in the molecular genetics of pituitary adenomas and related tumors. Stratakis CA. Expert Rev Endocrinol Metab; 2012 Nov; 7(6):593-598. PubMed ID: 30754126 [Abstract] [Full Text] [Related]
30. StemCells, Inc.: Clinical trials of stem cell therapies for CNS disorders. Interview with Martin McGlynn. McGlynn M. Regen Med; 2012 Nov; 7(6 Suppl):8-11. PubMed ID: 23210806 [Abstract] [Full Text] [Related]
31. Management of multiple myeloma: the impact of ixazomib's approval in Canada. Reece DE. Int J Hematol Oncol; 2016 Nov; 5(3):97-99. PubMed ID: 30302208 [Abstract] [Full Text] [Related]
32. Prof. Peter G. FEDOR-FREYBERGH, MD, DSc, Dr.h.c. mult. Maas L. Neuro Endocrinol Lett; 2021 Dec 21; 42(8):501-502. PubMed ID: 35596743 [Abstract] [Full Text] [Related]
33. Polycystic ovary syndrome, microbiomics and why you should be a little selfish with your time. Azziz R. Expert Rev Endocrinol Metab; 2013 Jul 21; 8(4):329-331. PubMed ID: 30736147 [Abstract] [Full Text] [Related]
34. Hans Küpper discusses science and venture capital. Küpper H. Drug Discov Today; 2004 Nov 01; 9(21):909-12. PubMed ID: 15501722 [Abstract] [Full Text] [Related]
35. Preliminary data on ASP2215: tolerability and efficacy in acute myeloid leukemia patients. Thom C. Future Oncol; 2015 Sep 01; 11(18):2499-501. PubMed ID: 26279055 [Abstract] [Full Text] [Related]
36. Contribution of late professor T. C. Tung to the experimental embryology of Amphioxus. In memory of the 20th anniversary of Professor T. C. Tung's death. Yan S. Dev Growth Differ; 1999 Oct 01; 41(5):503-22. PubMed ID: 10545024 [Abstract] [Full Text] [Related]
37. Interview with a quality leader: Kevin B. Weiss on measures in the ambulatory setting. Interview by Pamela K. Scarrow. Weiss KB. J Healthc Qual; 2008 Oct 01; 30(4):20-3. PubMed ID: 18680923 [Abstract] [Full Text] [Related]
38. Interview with Janet Woodcock: progress on the FDA's critical path initiative. Woodcock J. Biomark Med; 2009 Dec 01; 3(6):671-3. PubMed ID: 20477704 [Abstract] [Full Text] [Related]